HR Execs on the Move

BioCryst Pharmaceuticals, Inc.

www.biocryst.com

 
BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.biocryst.com
  • 4505 Emperor Blvd Ste 200
    Durham, NC USA 27703
  • Phone: 919.859.1302

Executives

Name Title Contact Details
Daniel Kadunce
Assoc. Director, Talent Acquisition Profile
Sylvia Dobo
Senior VP, Global Drug Safety and Pharmacovigilance Profile
Bonnie McDonald
Vice President Human Resources Profile
Raymond. Taylor
VP, Global Development & Product Team Leader ‰€“ Antivirals, FOP Profile
Helen Thackray
Chief Research and Development Officer Profile

Similar Companies

The Hamner Institutes for Health Sciences

The Hamner Institutes for Health Sciences is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProteinOne

ProteinOne is a Derwood, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenVault Corporation

GenVault Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Lycera

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells. Incorrect regulation can cause the immune system to attack healthy tissue as foreign, supporting onset and progression of autoimmune disease while disruption of anti-tumor immune responses can shield cancer cells from the immune system and allow them to proliferate. Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients. With senior leadership and a team of scientists who represent the best of their fields, Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world. Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation.